Search

Your search keyword '"Kawata, Kazuhito"' showing total 388 results
Start Over Author "Kawata, Kazuhito"
388 results on '"Kawata, Kazuhito"'

2. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Rossari, Federico, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo Alberto, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Soldà, Caterina, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Bruccoleri, Mariangela, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Foti, Silvia, Camera, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

5. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis

Author

Atsukawa, Masanori, Tsubota, Akihito, Kondo, Chisa, Toyoda, Hidenori, Takaguchi, Koichi, Nakamuta, Makoto, Watanabe, Tsunamasa, Morishita, Asahiro, Tani, Joji, Okubo, Hironao, Hiraoka, Atsushi, Nozaki, Akito, Chuma, Makoto, Kawata, Kazuhito, Uojima, Haruki, Ogawa, Chikara, Asano, Toru, Mikami, Shigeru, Kato, Keizo, Matsuura, Kentaro, Ikegami, Tadashi, Ishikawa, Toru, Tsuji, Kunihiko, Tada, Toshifumi, Tsutsui, Akemi, Senoh, Tomonori, Kitamura, Michika, Okubo, Tomomi, Arai, Taeang, Kohjima, Motoyuki, Morita, Kiyoshi, Akahane, Takehiro, Nishikawa, Hiroki, Iwasa, Motoh, Tanaka, Yasuhito, and Iwakiri, Katsuhiko

Published
2024
Full Text
View/download PDF

6. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Author

Camera, Silvia, Rimini, Margherita, Rossari, Federico, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Salani, Francesca, Marseglia, Mariarosaria, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Lonardi, Sara, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Persano, Mara, Foti, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

8. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices

Author

Tada, Fujimasa, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Naganuma, Atsushi, Kosaka, Hisashi, Matono, Tomomitsu, Kuroda, Hidekatsu, Yata, Yutaka, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Yokohama, Keisuke, Nishikawa, Hiroki, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Iijima, Hiroko, Kaibori, Masaki, Hiasa, Yoichi, and Kumada, Takashi

Published
2023
Full Text
View/download PDF

9. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Salani, Francesca, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Schirripa, Marta, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

10. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Kawaguchi, Takumi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Cammarota, Antonella, Burgio, Valentina, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

11. Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications

Author

Arai, Taeang, Takahashi, Hirokazu, Seko, Yuya, Toyoda, Hidenori, Hayashi, Hideki, Yamaguchi, Kanji, Iwaki, Michihiro, Yoneda, Masato, Shima, Toshihide, Fujii, Hideki, Morishita, Asahiro, Kawata, Kazuhito, Tomita, Kengo, Kawanaka, Miwa, Yoshida, Yuichi, Ikegami, Tadashi, Notsumata, Kazuo, Oeda, Satoshi, Atsukawa, Masanori, Kamada, Yoshihiro, Sumida, Yoshio, Fukushima, Hideaki, Miyoshi, Eiji, Aishima, Shinichi, Okanoue, Takeshi, Itoh, Yoshito, and Nakajima, Atsushi

Published
2024
Full Text
View/download PDF

12. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Rimassa, Lorenza, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

13. Ursodeoxycholic acid impairs liver‐infiltrating T‐cell chemotaxis through IFN‐γ and CX3CL1 production in primary biliary cholangitis

Author

Shimoyama, Shin, Kawata, Kazuhito, Ohta, Kazuyoshi, Chida, Takeshi, Suzuki, Tetsuro, Tsuneyama, Koichi, Shimoda, Shinji, Kurono, Nobuhito, Leung, Patrick SC, Gershwin, M Eric, Suda, Takafumi, and Kobayashi, Yoshimasa

Subjects
Biomedical and Clinical Sciences, Immunology, Chronic Liver Disease and Cirrhosis, Rare Diseases, Liver Disease, Digestive Diseases, Clinical Research, Oral and gastrointestinal, Adult, Aged, Aged, 80 and over, Chemokine CX3CL1, Chemotaxis, Cholagogues and Choleretics, Epithelial Cells, Female, Humans, Immunosuppression Therapy, Interferon-gamma, Jurkat Cells, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, T-Lymphocytes, Ursodeoxycholic Acid, CX3CL1, IFN&#8208, &#947, liver&#8208, infiltrating T cells, primary biliary cholangitis, ursodeoxycholic acid, IFN-γ, liver-infiltrating T cells
Abstract

Ursodeoxycholic acid (UDCA) is the primary treatment for primary biliary cholangitis (PBC), but its mechanism of action remains unclear. Studies suggest that UDCA enhances NF erythroid 2-related factor 2 (NFE2L2) expression and that the interaction between IFN-γ and C-X3-C motif chemokine ligand 1 (CX3CL1) facilitates biliary inflammation in PBC. Therefore, we examined the effects of UDCA on the expression of IFN-γ and CX3CL1 in in vitro and in vivo PBC models such as human liver tissue, a murine model, cell lines, and isolated human intrahepatic biliary epithelial cells (IHBECs). We observed a significant decrease in IFN-γ mRNA levels and positive correlations between IFN-γ and CX3CL1 mRNA levels post-UDCA treatment in PBC livers. NFE2L2-mediated transcriptional activation was significantly enhanced in UDCA-treated Jurkat cells. In 2-octynoic acid-immunized mice, IFN-γ production by liver-infiltrating T cells was dependent on NFE2L2 activation. IFN-γ significantly and dose-dependentlyinduced CX3CL1 expression, which was significantly decreased in HuCC-T1 cells and IHBECs upon UDCA treatment. These results suggest that UDCA-induced suppression of IFN-γ and CX3CL1 production attenuates the chemotactic and adhesive abilities of liver-infiltrating T cells in PBC.

Published
2021

15. Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study

Author

Atsukawa, Masanori, Tsubota, Akihito, Kondo, Chisa, Koyano, Kaori-Shioda, Ishikawa, Toru, Toyoda, Hidenori, Takaguchi, Koichi, Watanabe, Tsunamasa, Matsuura, Kentaro, Ogawa, Chikara, Hiraoka, Atsushi, Okubo, Hironao, Tateyama, Masakuni, Uojima, Haruki, Nozaki, Akito, Chuma, Makoto, Kato, Keizo, Mikami, Shigeru, Tani, Joji, Morishita, Asahiro, Kawata, Kazuhito, Tada, Toshifumi, Furuichi, Yoshihiro, Okubo, Tomomi, Kawano, Tadamichi, Arai, Taeang, Kawabe, Naoto, Kawamura, Naohiro, Ikegami, Tadashi, Nakamuta, Makoto, Shigefuku, Ryuta, Iwasa, Motoh, Tanaka, Yasuhito, Hatano, Masaru, and Iwakiri, Katsuhiko

Published
2023
Full Text
View/download PDF

16. Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, and Kumada, Takashi

Published
2023
Full Text
View/download PDF

17. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Niizeki, Takashi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Stefanini, Bernardo, Hiraoka, Atsushi, Sho, Takuya, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Campani, Claudia, Amadeo, Elisabeth, Rossari, Federico, Burgio, Valentina, Cascinu, Stefano, Scartozzi, Mario, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

18. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, and Kumada, Takashi

Published
2022
Full Text
View/download PDF

19. Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, and Kumada, Takashi

Published
2023
Full Text
View/download PDF

20. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Author

Casadei-Gardini, Andrea, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Persano, Mara, Della Corte, Angelo, Ratti, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Cascinu, Stefano, and Cucchetti, Alessandro

Published
2023
Full Text
View/download PDF

21. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study

Author

Fujii, Hideki, Iwaki, Michihiro, Hayashi, Hideki, Toyoda, Hidenori, Oeda, Satoshi, Hyogo, Hideyuki, Kawanaka, Miwa, Morishita, Asahiro, Munekage, Kensuke, Kawata, Kazuhito, Yamamura, Sakura, Sawada, Koji, Maeshiro, Tatsuji, Tobita, Hiroshi, Yoshida, Yuichi, Naito, Masafumi, Araki, Asuka, Arakaki, Shingo, Kawaguchi, Takumi, Noritake, Hidenao, Ono, Masafumi, Masaki, Tsutomu, Yasuda, Satoshi, Tomita, Eiichi, Yoneda, Masato, Kawada, Norifumi, Tokushige, Akihiro, Kamada, Yoshihiro, Takahashi, Hirokazu, Ueda, Shinichiro, Aishima, Shinichi, Sumida, Yoshio, Nakajima, Atsushi, and Okanoue, Takeshi

Published
2023
Full Text
View/download PDF

22. Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD

Author

Toyoda, Hidenori, Fujii, Hideki, Iwaki, Michihiro, Hayashi, Hideki, Oeda, Satoshi, Hyogo, Hideyuki, Kawanaka, Miwa, Morishita, Asahiro, Munekage, Kensuke, Kawata, Kazuhito, Yamamura, Sakura, Sawada, Koji, Maeshiro, Tatsuji, Tobita, Hiroshi, Yoshida, Yuichi, Naito, Masafumi, Araki, Asuka, Arakaki, Shingo, Kawaguchi, Takumi, Noritake, Hidenao, Ono, Masafumi, Masaki, Tsutomu, Yasuda, Satoshi, Tomita, Eiichi, Yoneda, Masato, Kawada, Norifumi, Tokushige, Akihiro, Kamada, Yoshihiro, Takahashi, Hirokazu, Ueda, Shinichiro, Aishima, Shinichi, Sumida, Yoshio, Nakajima, Atsushi, and Okanoue, Takeshi

Published
2023
Full Text
View/download PDF

23. WED-273 The performance of the enhanced liver fibrosis test by cardiometabolic risk factors in patients with metabolic dysfunction-associated steatotic liver disease

Author

Kawata, Kazuhito, primary, Takahashi, Hirokazu, additional, Arai, Taeang, additional, Seko, Yuya, additional, Chida, Takeshi, additional, Noritake, Hiedenao, additional, Toyoda, Hidenori, additional, Hayashi, Hideki, additional, Yamaguchi, Kanji, additional, Iwaki, Michihiro, additional, Yoneda, Masato, additional, Shima, Toshihide, additional, Fujii, Hideki, additional, Morishita, Asahiro, additional, Tomita, Kengo, additional, Kawanaka, Miwa, additional, Yoshida, Yuichi, additional, Ikegami, Tadashi, additional, Notsumata, Kazuo, additional, Oeda, Satoshi, additional, Atsukawa, Masanori, additional, Kamada, Yoshihiro, additional, Sumida, Yoshio, additional, Fukushima, Hideaki, additional, Miyoshi, Eiji, additional, Aishima, Shinichi, additional, Okanoue, Takeshi, additional, Itoh, Yoshito, additional, and Nakajima, Atsushi, additional

Published
2024
Full Text
View/download PDF

24. C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

Author

Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Aoki, Tomoko, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Hiasa, Yoichi, and Kudo, Masatoshi

Published
2022
Full Text
View/download PDF

25. Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Toyoda, Hidenori, Ogawa, Chikara, Nishikawa, Hiroki, Nishimura, Takashi, Kawata, Kazuhito, and Kosaka, Hisashi

Subjects
CONVERSION therapy, NEUTROPHIL lymphocyte ratio, OVERALL survival, HEPATOCELLULAR carcinoma, SURVIVAL rate, BEVACIZUMAB
Abstract

Summary: Aim: This study aims to investigate the predictive factors for conversion therapy in patients with unresectable hepatocellular carcinoma (uHCC) and to evaluate the prognosis of conversion cases by comparing them with partial response (PR) and complete response (CR) cases. Methods: In this retrospective multicentre study, we included a total of 946 uHCC patients treated with atezolizumab and bevacizumab (Atez/Bev) from September 2020 to September 2023. Results: Out of the patients, 43 (4.5%) received conversion therapy following Atez/Bev treatment. The overall response rate was 65.1% and 23.7% in the conversion and non‐conversion group, respectively, with a statistical significance (p < 0.001). Multivariate analyses identified that BCLC stage B or an earlier stage (p = 0.045), absence of macrovascular invasion and extrahepatic spread (p = 0.045), and a low value of neutrophil to lymphocyte ratio (p = 0.04) were significantly favourable predictive factors associated with conversion therapy. The conversion group showed significantly better survival compared to the non‐conversion group (p < 0.001). In the landmark analysis at 6, 12 and 18 months, the conversion group exhibited better survival compared to PR patients in the non‐conversion group (p = 0.04, 0.01 and 0.03, respectively) and there were no significant differences in the overall survival (OS) between the conversion group and patients who achieved a CR (p = 0.7, 1.0 and 0.3, respectively). Conclusions: Patients with low tumour burden and low value of NLR were more likely to undergo conversion therapy. The OS of patients undergoing conversion therapy showed better survival compared to those achieving PR and was comparable to those with CR patients. Conversion therapy could be considered if feasible. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Validation study of age‐independent fibrosis score (Fibrosis‐3 index) in patients with metabolic dysfunction‐associated steatotic liver disease.

Author

Nouso, Kazuhiro, Kawanaka, Miwa, Fujii, Hideki, Kariyama, Kazuya, Toyoda, Hidenori, Iwaki, Michihiro, Hayashi, Hideki, Oeda, Satoshi, Hyogo, Hideyuki, Morishita, Asahiro, Munekage, Kensuke, Kawata, Kazuhito, Tsutsumi, Tsubasa, Sawada, Koji, Maeshiro, Tatsuji, Tobita, Hiroshi, Yoshida, Yuichi, Naito, Masafumi, Araki, Asuka, and Arakaki, Shingo

Subjects
HEPATIC fibrosis, RECEIVER operating characteristic curves, TREATMENT effectiveness, AGE groups, LIVER diseases
Abstract

Background and Aims: Because the accuracy of the Fibrosis‐4 (FIB‐4) index for predicting liver fibrosis changes with age, the need for different cut‐offs in various age groups has frequently been discussed. We developed the age‐independent score, the Fibrosis‐3 (FIB‐3) index, and have shown its usefulness in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). This study aimed to validate the diagnostic ability of the FIB‐3 index to predict fibrosis progression using a large new patient cohort. Methods: The ability of the FIB‐3 index to predict liver fibrosis was analyzed by comparing it with that of the FIB‐4 index using data from 1398 patients with MASLD enrolled in the Asia‐based clinical outcome NAFLD study. Results: The areas under the receiver operating characteristic curves for predicting fibrosis stage F3 or higher were not different between the FIB‐3 and FIB‐4 indices in the entire cohort. Using the single ideal cut‐offs of the indices (3.41 for FIB‐3 index and 2.01 for FIB‐4 index), the predictive accuracy of the FIB‐3 index was not significantly different from that of the FIB‐4 index among patients aged <60 years; however, the accuracy of the FIB‐3 index was significantly higher than that of the FIB‐4 index in those aged ≥60 years (0.645 and 0.529, respectively; p < 0.0001). Conclusion: The high ability of the FIB‐3 index with a single cut‐off to predict liver fibrosis in patients with MASLD was confirmed. The FIB‐3 index could serve as a useful tool for assessing liver fibrosis regardless of age. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case–control study

Author

Matsumoto, Kosuke, Ohfuji, Satoko, Abe, Masanori, Komori, Atsumasa, Takahashi, Atsushi, Fujii, Hideki, Kawata, Kazuhito, Noritake, Hidenao, Tadokoro, Tomoko, Honda, Akira, Asami, Maiko, Namisaki, Tadashi, Ueno, Masayuki, Sato, Ken, Kakisaka, Keisuke, Arakawa, Mie, Ito, Takanori, Tanaka, Kazunari, Matsui, Takeshi, Setsu, Toru, Takamura, Masaaki, Yasuda, Satoshi, Katsumi, Tomohiro, Itakura, Jun, Sano, Tomoya, Tamura, Yamato, Miura, Ryo, Arizumi, Toshihiko, Asaoka, Yoshinari, Uno, Kiyoko, Nishitani, Ai, Ueno, Yoshiyuki, Terai, Shuji, Takikawa, Yasuhiro, Morimoto, Youichi, Yoshiji, Hitoshi, Mochida, Satoshi, Ikegami, Tadashi, Masaki, Tsutomu, Kawada, Norifumi, Ohira, Hiromasa, and Tanaka, Atsushi

Published
2022
Full Text
View/download PDF

28. A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis

Author

Hitomi, Yuki, primary, Ueno, Kazuko, additional, Aiba, Yoshihiro, additional, Nishida, Nao, additional, Kono, Michihiro, additional, Sugihara, Mitsuki, additional, Kawai, Yosuke, additional, Kawashima, Minae, additional, Khor, Seik-Soon, additional, Sugi, Kazuhiro, additional, Kouno, Hirotaka, additional, Kouno, Hiroshi, additional, Naganuma, Atsushi, additional, Iwamoto, Satoru, additional, Katsushima, Shinji, additional, Furuta, Kiyoshi, additional, Nikami, Toshiki, additional, Mannami, Tomohiko, additional, Yamashita, Tsutomu, additional, Ario, Keisuke, additional, Komatsu, Tatsuji, additional, Makita, Fujio, additional, Shimada, Masaaki, additional, Hirashima, Noboru, additional, Yokohama, Shiro, additional, Nishimura, Hideo, additional, Sugimoto, Rie, additional, Komura, Takuya, additional, Ota, Hajime, additional, Kojima, Motoyuki, additional, Nakamuta, Makoto, additional, Fujimori, Naoyuki, additional, Yoshizawa, Kaname, additional, Mano, Yutaka, additional, Takahashi, Hironao, additional, Hirooka, Kana, additional, Tsuruta, Satoru, additional, Sato, Takeaki, additional, Yamasaki, Kazumi, additional, Kugiyama, Yuki, additional, Motoyoshi, Yasuhide, additional, Suehiro, Tomoyuki, additional, Saeki, Akira, additional, Matsumoto, Kosuke, additional, Nagaoka, Shinya, additional, Abiru, Seigo, additional, Yatsuhashi, Hiroshi, additional, Ito, Masahiro, additional, Kawata, Kazuhito, additional, Takaki, Akinobu, additional, Arai, Kuniaki, additional, Arinaga, Teruko, additional, Abe, Masanori, additional, Harada, Masaru, additional, Taniai, Makiko, additional, Zeniya, Mikio, additional, Ohira, Hiromasa, additional, Shimoda, Shinji, additional, Komori, Atsumasa, additional, Tanaka, Atsushi, additional, Ishigaki, Kazuyoshi, additional, Nagasaki, Masao, additional, Tokunaga, Katsushi, additional, and Nakamura, Minoru, additional

Published
2024
Full Text
View/download PDF

29. Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan

Author

Tsutsumi, Tsubasa, primary, Kawaguchi, Takumi, additional, Fujii, Hideki, additional, Kamada, Yoshihiro, additional, Takahashi, Hirokazu, additional, Kawanaka, Miwa, additional, Sumida, Yoshio, additional, Iwaki, Michihiro, additional, Hayashi, Hideki, additional, Toyoda, Hidenori, additional, Oeda, Satoshi, additional, Hyogo, Hideyuki, additional, Morishita, Asahiro, additional, Munekage, Kensuke, additional, Kawata, Kazuhito, additional, Sawada, Koji, additional, Maeshiro, Tatsuji, additional, Tobita, Hiroshi, additional, Yoshida, Yuichi, additional, Naito, Masafumi, additional, Araki, Asuka, additional, Arakaki, Shingo, additional, Noritake, Hidenao, additional, Ono, Masafumi, additional, Masaki, Tsutomu, additional, Yasuda, Satoshi, additional, Tomita, Eiichi, additional, Yoneda, Masato, additional, Tokushige, Akihiro, additional, Ueda, Shinichiro, additional, Aishima, Shinichi, additional, Nakajima, Atsushi, additional, and Okanoue, Takeshi, additional

Published
2024
Full Text
View/download PDF

30. Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Foti, Silvia, additional, Camera, Silvia, additional, Stefanini, Bernardo, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei-Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2024
Full Text
View/download PDF

31. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.

Author

Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Nishikawa, Hiroki, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Koshiyama, Yuichi, Toyoda, Hidenori, Ogawa, Chikara, Hatanaka, Takeshi, Kakizaki, Satoru, and Kawata, Kazuhito

Subjects
CLINICAL trials, HEPATOCELLULAR carcinoma, ATEZOLIZUMAB, BEVACIZUMAB, OVERALL survival
Abstract

Summary: Background: Atezolizumab plus bevacizumab (Atezo/Bev) is frequently selected as the primary systemic therapy for hepatocellular carcinoma (HCC). Aims: To investigate the outcomes of patients with HCC treated with Atezo/Bev in a real‐world setting based on whether they met the inclusion criteria for the phase 3 IMbrave150 trial. Methods: A total of 936 patients were enrolled. There were 404 patients who met the inclusion criteria of the phase 3 IMbrave150 trial (IMbrave150 group) and 532 who did not (non‐IMbrave150 group). Results: Median progression‐free survival (PFS) in the IMbrave150 and non‐IMbrave150 groups was 7.4 months and 5.6 months (p = 0.002). Multivariable analysis revealed that non‐B, non‐C HCC aetiology (hazard ratio [HR], 1.173), α‐fetoprotein ≥100 ng/mL (HR, 1.472), Barcelona Clinic Liver Cancer stage ≥ C (HR, 1.318), and modified albumin–bilirubin (mALBI) grade 2b or 3 (HR, 1.476) are independently associated with PFS. Median overall survival (OS) in the IMbrave150 and non‐Imbrave150 groups was 26.5 and 18.8 months (p < 0.001). Multivariable analysis revealed that Eastern Cooperative Oncology Group performance status ≥2 (HR, 1.986), α‐fetoprotein ≥100 ng/mL (HR, 1.481), and mALBI grade 2b or 3 (HR, 2.037) are independently associated with OS. In subgroup analysis, there were no significant differences in PFS or OS between these groups among patients with mALBI grade 1 or 2a. Conclusions: Patients who are treated with Atezo/Bev and meet the inclusion criteria for the phase 3 IMbrave150 trial, as well as those who do not meet the inclusion criteria but have good liver function, have a good prognosis for survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study.

Author

Tanifuji, Ayaka, Ohfuji, Satoko, Matsumoto, Kosuke, Abe, Masanori, Komori, Atsumasa, Takahashi, Atsushi, Kawata, Kazuhito, Sato, Ken, Joshita, Satoru, Umemura, Takeji, Ueno, Masayuki, Nakayama, Nobuaki, Kakisaka, Keisuke, Arinaga‐Hino, Teruko, Ito, Koichi, Kanai, Sachiko, Miura, Ryo, Arizumi, Toshihiko, Asaoka, Yoshinari, and Ito, Takanori

Subjects
CHOLANGITIS, SARS-CoV-2, COVID-19 vaccines, VACCINE effectiveness, BUDD-Chiari syndrome, AUTOIMMUNE hepatitis
Abstract

Aim: There are few data regarding the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines in patients with intractable hepatobiliary diseases. We conducted a multicenter, questionnaire‐based, cross‐sectional study to determine the safety and effectiveness of the SARS‐CoV‐2 vaccines in Japanese patients with intractable hepatobiliary disease. Methods: Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd–Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study. Participants were asked to complete a questionnaire regarding their characteristics, vaccination status, post‐vaccination adverse effects, and SARS‐CoV‐2 infection. Additionally, liver disease status, treatment regimens, and liver function test values pre‐ and post‐vaccination were collected. Results: The survey was conducted from September 2021 to May 2022, and 528 patients (220 AIH, 251 primary biliary cholangitis, 6 AIH– primary biliary cholangitis/primary sclerosing cholangitis overlap, 39 primary sclerosing cholangitis, 4 Budd–Chiari syndrome, 5 idiopathic portal hypertension, and 3 extrahepatic portal vein obstruction) participated in the study. Post‐vaccination adverse effects were comparable to those observed in the general population. Post‐vaccination liver injuries classified as grade 1 or higher were observed in 83 cases (16%), whereas grades 2 and 3 were observed in only six cases (1.1%); AIH‐like liver injury requiring treatment was not observed. Overall, 12 patients (2.3%) were infected with SARS‐CoV‐2, and only one patient was infected 6 months after the second vaccination. Conclusion: SARS‐CoV‐2 vaccines demonstrated satisfactory safety and effectiveness in Japanese patients with intractable hepatobiliary diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis

Author

Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Iijima, Hiroko, and Hiasa, Yoichi

Published
2022
Full Text
View/download PDF

34. Incidental detection of upper gastrointestinal epithelial neoplasia by screening endoscopy prior to endoscopic ultrasonography in patients with pancreaticobiliary disease

Author

Kaneko, Junichi, primary, Yamada, Takanori, additional, Sasada, Yuzo, additional, Watahiki, Moeka, additional, Kosugi, Toshikatsu, additional, Kusama, Daisuke, additional, Tamakoshi, Hiroki, additional, Niwa, Tomoyuki, additional, Takinami, Masaki, additional, Tsuji, Atsushi, additional, Nishino, Masafumi, additional, Takahashi, Yurimi, additional, Kawata, Kazuhito, additional, and Sugimoto, Ken, additional

Published
2024
Full Text
View/download PDF

35. Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications

Author

Arai, Taeang, primary, Takahashi, Hirokazu, additional, Seko, Yuya, additional, Toyoda, Hidenori, additional, Hayashi, Hideki, additional, Yamaguchi, Kanji, additional, Iwaki, Michihiro, additional, Yoneda, Masato, additional, Shima, Toshihide, additional, Fujii, Hideki, additional, Morishita, Asahiro, additional, Kawata, Kazuhito, additional, Tomita, Kengo, additional, Kawanaka, Miwa, additional, Yoshida, Yuichi, additional, Ikegami, Tadashi, additional, Notsumata, Kazuo, additional, Oeda, Satoshi, additional, Atsukawa, Masanori, additional, Kamada, Yoshihiro, additional, Sumida, Yoshio, additional, Fukushima, Hideaki, additional, Miyoshi, Eiji, additional, Aishima, Shinichi, additional, Okanoue, Takeshi, additional, Itoh, Yoshito, additional, and Nakajima, Atsushi, additional

Published
2023
Full Text
View/download PDF

36. α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Burgio, Valentina, additional, Piscaglia, Fabio, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei‐Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2023
Full Text
View/download PDF

37. Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

Author

Ohama, Hideko, primary, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Naganuma, Atsushi, additional, Kosaka, Hisashi, additional, Matono, Tomomitsu, additional, Kuroda, Hidekatsu, additional, Yata, Yutaka, additional, Tanaka, Hironori, additional, Nishikawa, Hiroki, additional, Shibata, Hiroshi, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Iijima, Hiroko, additional, Kaibori, Masaki, additional, Hiasa, Yoichi, additional, and Kumada, Takashi, additional

Published
2023
Full Text
View/download PDF

38. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Ohama, Hideko, primary, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Hatanaka, Takeshi, additional, Tani, Joji, additional, Takaguchi, Koichi, additional, Atsukawa, Masanori, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Tajiri, Kazuto, additional, Ishikawa, Toru, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Nishimura, Takashi, additional, Ogawa, Chikara, additional, Satoru, Kakizaki, additional, Shimada, Noritomo, additional, Naganuma, Atsushi, additional, Kawata, Kazuhito, additional, Kosaka, Hisashi, additional, Kuroda, Hidekatsu, additional, Matono, Tomomitsu, additional, Yata, Yutaka, additional, Ochi, Hironori, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Yokohama, Keisuke, additional, Nishikawa, Hiroki, additional, Imai, Michitaka, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Iijima, Hiroko, additional, Kaibori, Masaki, additional, Hiasa, Yoichi, additional, and Kumada, Takashi, additional

Published
2023
Full Text
View/download PDF

39. Utility of screening esophagogastroduodenoscopy performed sequentially with endoscopic ultrasonography

Author

Kaneko, Junichi, primary, Yamada, Takanori, additional, Sasada, Yuzo, additional, Watahiki, Moeka, additional, Kosugi, Toshikatsu, additional, Kusama, Daisuke, additional, Tamakoshi, Hiroki, additional, Niwa, Tomoyuki, additional, Takinami, Masaki, additional, Tsuji, Atsushi, additional, Nishino, Masafumi, additional, Takahashi, Yurimi, additional, Kawata, Kazuhito, additional, and Sugimoto, Ken, additional

Published
2023
Full Text
View/download PDF

40. Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

Author

Iavarone, Massimo, primary, Alimenti, Eleonora, additional, Tada, Toshifumi, additional, Shimose, Shigeo, additional, Suda, Goki, additional, Yoo, Changhoon, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Tosetti, Giulia, additional, Marra, Fabio, additional, Vivaldi, Caterina, additional, Conti, Fabio, additional, Schirripa, Marta, additional, Iwamoto, Hideki, additional, Sho, Takuya, additional, Lee, So Heun, additional, Rizzato, Mario Domenico, additional, Tonnini, Matteo, additional, Rimini, Margherita, additional, Campani, Claudia, additional, Masi, Gianluca, additional, Foschi, Francesco, additional, Bruccoleri, Mariangela, additional, Kawaguchi, Takumi, additional, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Atsukawa, Masanori, additional, Fukunishi, Shinya, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Casadei-Gardini, Andrea, additional, and Lampertico, Pietro, additional

Published
2023
Full Text
View/download PDF

41. Platelet–lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis

Author

Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Michitaka, Kojiro, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Fukunishi, Shinya, Ohama, Hideko, Kawata, Kazuhito, Nakamura, Shinichiro, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Arai, Taeang, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, and Hiasa, Yoichi

Published
2021
Full Text
View/download PDF

42. Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

Author

Tanaka, Kazunari, primary, Tsuji, Kunihiko, additional, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Naganuma, Atsushi, additional, Kosaka, Hisashi, additional, Matono, Tomomitsu, additional, Kuroda, Hidekatsu, additional, Yata, Yutaka, additional, Ohama, Hideko, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Yokohama, Keisuke, additional, Nishikawa, Hiroki, additional, Imai, Michitaka, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Iijima, Hiroko, additional, Kaibori, Masaki, additional, Hiasa, Yoichi, additional, and Kumada, Takashi, additional

Published
2023
Full Text
View/download PDF

43. Role of hepcidin upregulation and proteolytic cleavage of ferroportin 1 in hepatitis C virus-induced iron accumulation

Author

Ohta, Kazuyoshi, primary, Ito, Masahiko, additional, Chida, Takeshi, additional, Nakashima, Kenji, additional, Sakai, Satoshi, additional, Kanegae, Yumi, additional, Kawasaki, Hideya, additional, Aoshima, Takuya, additional, Takabayashi, Shuji, additional, Takahashi, Hirotaka, additional, Kawata, Kazuhito, additional, Shoji, Ikuo, additional, Sawasaki, Tatsuya, additional, Suda, Takafumi, additional, and Suzuki, Tetsuro, additional

Published
2023
Full Text
View/download PDF

44. A case of hepatitis B virus-infected patient with bevacizumab-related severe intratumor hemorrhage of large hepatocellular carcinoma (HCC)

Author

Matsumoto, Moe, primary, Noritake, Hidenao, additional, Yamashita, Maho, additional, Hanaoka, Tomohiko, additional, Umemura, Masahiro, additional, Kitsugi, Kensuke, additional, Takatori, Shingo, additional, Ohta, Kazuyoshi, additional, Ito, Jun, additional, Chida, Takeshi, additional, and Kawata, Kazuhito, additional

Published
2023
Full Text
View/download PDF

45. Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function

Author

Hiraoka, Atsushi, primary, Kumada, Takashi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Naganuma, Atsushi, additional, Kosaka, Hisashi, additional, Matono, Tomomitsu, additional, Kuroda, Hidekatsu, additional, Yata, Yutaka, additional, Ohama, Hideko, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Yokohama, Keisuke, additional, Imai, Michitaka, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Iijima, Hiroko, additional, Kaibori, Masaki, additional, and Hiasa, Yoichi, additional

Published
2023
Full Text
View/download PDF

46. Prognostic value of serum ALP levels during additional treatment in Japanese patients with primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate

Author

Takeuchi, Akihito, primary, Matsumoto, Kosuke, additional, Komori, Atsumasa, additional, Abe, Masanori, additional, Namisaki, Tadashi, additional, Kawata, Kazuhito, additional, Ninomiya, Masashi, additional, Fujii, Hideki, additional, Takahashi, Atsushi, additional, Jong-Hon, KANG, additional, Takamura, Masaaki, additional, Arakawa, Mie, additional, Joshita, Satoru, additional, Sato, Ken, additional, Nomura, Takako, additional, Kakisaka, Keisuke, additional, Kaneko, Akira, additional, Kikuchi, Kentaro, additional, Masaki, Tsutomu, additional, Umemura, Takeji, additional, Honda, Akira, additional, Ohira, Hiromasa, additional, Kawada, Norifumi, additional, Yoshiji, Hitoshi, additional, Mochida, Satoshi, additional, and Tanaka, Atsushi, additional

Published
2023
Full Text
View/download PDF

47. Serum levels of type IV collagen 7S can predict liver-related mortality and events as well as advanced fibrosis: a multi-center study

Author

Ishiba, Hiroshi, primary, Sumida, Yoshio, additional, Kamada, Yoshihiro, additional, Fujii, Hideki, additional, Iwaki, Michihiro, additional, Hayashi, Hideki, additional, Toyoda, Hidenori, additional, Oeda, Satoshi, additional, Hyogo, Hideyuki, additional, Kawanaka, Miwa, additional, Morishita, Asahiro, additional, Munekage, Kensuke, additional, Kawata, Kazuhito, additional, Tsutsumi, Tsubasa, additional, Sawada, Koji, additional, Maeshiro, Tatsuji, additional, Tobita, Hiroshi, additional, Yoshida, Yuichi, additional, Naito, Masafumi, additional, Araraki, Shingo, additional, Kawaguchi, Takumi, additional, Noritake, Hiedenao, additional, Ono, Masafumi, additional, Masaki, Tsutomu, additional, Yasuda, Satoshi, additional, Tomita, Eiichi, additional, Yoneda, Masato, additional, Tokushige, Akihiro, additional, Takahashi, Hirokazu, additional, Ueda, Shinichiro, additional, Nakajima, Atsushi, additional, and Okanoue, Takeshi, additional

Published
2023
Full Text
View/download PDF

48. Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib

Author

Iavarone, Massimo, primary, Alimenti, Eleonora, additional, Tada, Toshifumi, additional, Shigeo, Shimose, additional, Suda, Goki, additional, Yoo, Changhoon, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Gardini, Andrea Casadei, additional, Marra, Fabio, additional, Vivaldi, Caterina, additional, Conti, Fabio, additional, Schirripa, Marta, additional, Iwamoto, Hideki, additional, Sho, Takuya, additional, Leo, So Heun, additional, Rizzato, Mario Domenico, additional, Tonnini, Matteo, additional, Rimini, Margherita, additional, Campani, Claudia, additional, Masi, Gianluca, additional, Foschi, Francesco, additional, Bruccoleri, Mariangela, additional, Kawaguchi, Takumi, additional, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Atsukawa, Masanori, additional, Fukunishi, Shinya, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Kawata, Kazuhito, additional, Tada, Faujimasa, additional, Ohama, Hideko, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Tosetti, Giulia, additional, and Lampertico, Pietro, additional

Published
2023
Full Text
View/download PDF

49. Age‐dependent effects of diabetes and obesity on liver‐related events in non‐alcoholic fatty liver disease: Subanalysis of CLIONE in Asia

Author

Seko, Yuya, Kawanaka, Miwa, Fujii, Hideki, Iwaki, Michihiro, Hayashi, Hideki, Toyoda, Hidenori, Oeda, Satoshi, Hyogo, Hideyuki, Morishita, Asahiro, Munekage, Kensuke, Kawata, Kazuhito, Yamamura, Sakura, Sawada, Koji, Maeshiro, Tatsuji, Tobita, Hiroshi, Yoshida, Yuichi, Naito, Masafumi, Araki, Asuka, Arakaki, Shingo, Kawaguchi, Takumi, Noritake, Hidenao, Ono, Masafumi, Masaki, Tsutomu, Yasuda, Satoshi, Tomita, Eiichi, Yoneda, Masato, Tokushige, Akihiro, Kamada, Yoshihiro, Takahashi, Hirokazu, Ueda, Shinichiro, Aishima, Shinichi, Sumida, Yoshio, Okanoue, Takeshi, Itoh, Yoshito, Nakajima, Atsushi, and Japan Study Group of Nonalcoholic Fatty Liver Disease

Subjects
2型糖尿病, nonalcoholic fatty liver disease, Carcinoma, Hepatocellular, 肝細胞癌, type 2 diabetes mellitus, CLIONE in Asia, 肥満, BMI, Non-alcoholic Fatty Liver Disease, Humans, Animals, Obesity, nonalcoholic steatohepatitis, Retrospective Studies, 線維症, Clione, Hepatology, Liver Neoplasms, Gastroenterology, hepatocellular carcinoma, 非アルコール性脂肪性肝疾患, Middle Aged, Fibrosis, age, Diabetes Mellitus, Type 2, 非アルコール性脂肪性肝炎, liver-related events
Abstract

Older age, type 2 diabetes mellitus (T2DM), and obesity are known risk factors for liver-related events (LREs). We investigated the impacts of T2DM and obesity on LRE according to age in Japanese patients with non-alcoholic fatty liver disease (NAFLD).We performed a subanalysis of a retrospective cohort study (CLIONE in Asia), including 1395 patients with biopsy-proven NAFLD. The median follow-up was 4.6 years.The median age was 57 years, and 36.2% had T2DM. The median body mass index (BMI) was 27.4, and 28.5% were severely obese (BMI ≥ 30). During follow-up, 37 patients developed hepatocellular carcinoma (HCC), and 58 patients developed LRE. In patients younger than 65 years, advanced fibrosis (hazard ratio [HR] 7.69, P 0.001) and T2DM (HR 3.37, P = 0.017) were HCC risk factors, and advanced fibrosis (HR 9.40, P 0.001) and T2DM (HR 2.51, P = 0.016) were LRE risk factors. In patients 65 years and older, advanced fibrosis (HR 4.24, P = 0.010) and obesity (HR 4.60, P = 0.006) were HCC risk factors, and advanced fibrosis (HR 4.22, P = 0.002) and obesity (HR 4.22, P = 0.002) were LRE risk factors.Type 2 diabetes mellitus and obesity contributed to LRE in younger and older patients, respectively, along with advanced fibrosis. Therefore, controlling T2DM in patients younger than 65 years and controlling weight in patients 65 years and older could prevent LRE. The development of age-dependent screening and management strategies is necessary for patients with NAFLD.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results